Clinical trial
Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA…
NCT00307125 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00307125 |
|---|---|
| Title | Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies |
| Official title | B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies Will Result in Inhibition of Alloantibody Production and Attenuation of Chronic Humoral Rejection |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Clinical Trials in Organ Transplantation Cooperative Clinical Trials in Pediatric Transplantation (CCTPT) |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Transplant, Kidney Transplant Recipient, Graft Function/Survival, de Novo HLA Antibodies Development |
| Intervention type | Drug |
| Interventions | Rituximab plus immunosuppression, Placebo plus immunosuppression |
| Enrollment | 757 |
| Start date | Mar 1, 2006 |
| Primary completion | Dec 1, 2012 |
| Completion | Dec 1, 2012 |
| First posted | Mar 27, 2006 |
| Last update posted | Mar 23, 2015 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: